Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses

Diabetic cardiomyopathy (DCM) is the principal cause of death in people with diabetes. However, there is currently no effective strategy to prevent the development of DCM. Although cyclovirobuxine D (CVB-D) has been widely used to treat multiple cardiovascular diseases, the possible beneficial effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Zhaohui, Fu, Lingyun, Xu, Yini, Hu, Xiaoxia, Yang, Hong, Zhang, Yanyan, Luo, Hong, Gan, Shiquan, Tao, Ling, Liang, Guiyou, Shen, Xiangchun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156511/
https://www.ncbi.nlm.nih.gov/pubmed/32286474
http://dx.doi.org/10.1038/s41598-020-63498-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156511/
https://www.ncbi.nlm.nih.gov/pubmed/32286474
http://dx.doi.org/10.1038/s41598-020-63498-3

Ejemplares similares